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Abstract
The non-immune binding of immunoglobulins by bacteria is thought to contribute to the pathogenesis of infections. M-
related proteins (Mrp) are group A streptococcal (GAS) receptors for immunoglobulins, but it is not known if this
binding has any impact on virulence. To further investigate the binding of immunoglobulins to Mrp, we engineered
mutants of an M type 4 strain of GAS by inactivating the genes for mrp, emm, enn, sof, and sfbX and tested these
mutants in IgG-binding assays. Inactivation of mrp dramatically decreased the binding of human IgG, whereas
inactivation of emm, enn, sof, and sfbx had only minor effects, indicating that Mrp is a major IgG-binding protein.
Binding of human immunoglobulins to a purified, recombinant form of Mrp indicated that it selectively binds to the Fc
domain of human IgG, but not IgA or IgM and that it preferentially bound subclasses IgG1>IgG4>IgG2>IgG3.
Recombinant proteins encompassing different regions of Mrp were engineered and used to map its IgG-binding
domain to its A-repeat region and a recombinant protein with 3 A-repeats was a better inhibitor of IgG binding than
one with a single A-repeat. A GAS mutant expressing Mrp with an in-frame deletion of DNA encoding the A-repeats
had a dramatically reduced ability to bind human IgG and to grow in human blood. Mrp exhibited host specificity in
binding IgG; human IgG was the best inhibitor of the binding of IgG followed by pig, horse, monkey, and rabbit IgG.
IgG from goat, mouse, rat, cow, donkey, chicken, and guinea pig were poor inhibitors of binding. These findings
indicate that Mrp preferentially binds human IgG and that this binding contributes to the ability of GAS to resist
phagocytosis and may be a factor in the restriction of GAS infections to the human host.
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Introduction
The group A streptococcus, Streptococcus pyogenes, is an
important human pathogen that is estimated to be the ninth
leading cause of deaths due to microbial infections worldwide
[1]. Members of the M protein family are key virulence factors
that contribute to the pathogenesis of S. pyogenes infections
and their binding of blood proteins, such as complement
regulatory proteins, plasminogen, albumin, fibrinogen, and
immunoglobulins, is thought to contribute to pathogenesis
[2-14].
The M protein family is composed of M protein (Emm), M-
related protein (Mrp), and an M-like protein (Enn), which are
part of the Mga regulon (Figure 1). The components of the Mga
regulon can vary depending upon the serotype. Some
serotypes express only Emm (Pattern A), whereas other
serotypes express Emm, Mrp and/or Enn (Figure 1).
Interestingly, it appears that some of the functions of Emm in
those serotypes that express only Emm (pattern A) are shifted
to other members of the M protein family in those serotypes
that express Mrp and Enn (patterns C, D, and E). For example,
Emm binds fibrinogen in pattern A serotypes whereas Mrp is
the major fibrinogen-binding protein in pattern D and E
serotypes [3,5,7,11].
Infections caused by S. pyogenes are almost entirely
restricted to humans, but the molecular basis for this host
preference is poorly understood. Plasminogen binding has
been linked to host specificity of group A streptococcal
infections [15], and the ability of S. pyogenes to selectively bind
immunoglobulins from certain species is thought to contribute
to this host specificity and to virulence. Mrp is a major surface
protein of S. pyogenes that has been shown to bind human IgG
[16-18], but there is no evidence indicating that this binding has
a role in virulence. Herein, we present our findings that support
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a role for Mrp-IgG interactions as a factor contributing to
virulence and host specificity of S. pyogenes.
Materials and Methods
Reagents
Peroxidase-labeled, human IgG, IgM, IgA and the unlabeled
F(ab’)2 and Fc fragments of human IgG were purchased from
Jackson ImmunoResearch Labs, Inc. (West Grove, PA).
Unlabeled animal IgG and sera were obtained from Sigma
Aldrich (St. Louis, MO) and Innovative Research (Novi, MI).
Human IgG1, IgG2, IgG3 and IgG4 were obtained from Athens
Research & Technology, Inc. (Athens, GA). Human,
plasminogen-free fibrinogen was purchased from Calbiochem
(La Jolla, CA) and biotinylated by the method of Bayer et al.
[19]. Neutravidin-peroxidase was obtained from Pierce
(Rockford, IL). The preparation of rabbit antiserum against a
synthetic peptide copying amino acid residues 3-17 of Mrp4
(anti-sMrp4(3-17)) and residues 1-30 of Emm4 (anti-
sEmm4(1-30)) was previously described [5].
Bacterial strains, mutants and growth conditions
The construction of mutants utilizing the parental strain M
type 4 S. pyogenes (SP4) was previously described [5]. These
consisted of MP4, an Mrp-negative mutant; AR4, an Emm-
negative mutant; EP4, an Enn-negative mutant; SF4, a SOF-
negative mutant; and DS4, an Sof-negative and Sfbx-negative
mutant. The mutant SP4ΔA, which expresses Mrp in which the
A-repeats were deleted in-frame, was constructed by cutting
the desired sequences from the pTrcHis vector that contained
an insert of rMrpΔA DNA (see below, cloning of rMrp for
details) and ligating the insert into pG+Host9, a temperature-
sensitive shuttle vector generously provided by E. Maguin [20].
The vector was then introduced into SP4 via allelic exchange
and a mutant expressing Mrp with an in-frame deletion of the
A-repeats was selected by previously described methods [5].
The strains were grown overnight at 37°C in Todd-Hewitt broth
supplemented with 1% yeast extract (THY) unless indicated
otherwise.
Cloning, expression, and purification of recombinant
Mrp
DNA encoding the desired sequences of Mrp4 were
amplified by PCR, ligated into pTrcHis, introduced into
Escherichia coli Top10, expressed as histidine fusion products,
and purified by metal affinity chromatography as previously
described [5]. The recombinant proteins consisted of
rMrp(1-328), rMrp(150-255), rMrp(150-185), rMrp(256-328),
rMrp(1-184), rMrp(97-197). The numbers in each case indicate
the amino acid residues that are spanned in the mature form of
Mrp4. rMrpΔA, in which the DNA encoding the A-repeats was
Figure 1.  Variations of the Mga regulon.  Mga (multigene activator) is a positive regulator of a number of streptococcal genes.
The most prominent of these are the family of M proteins whose genes are tandemly linked. sof (serum opacity factor) and sfbx
(streptococcal fibronectin binding protein x) are bicistronic and are also regulated by Mga, but are located some distance away.
emm encodes for M protein, mrp encodes M-related proteins, enn encodes an M-like protein that binds IgA, and scpa encodes a
C5a peptidase. Some serotypes contain only mga, emm, and scpa (pattern A). Other serotypes contain one or more of the
remaining genes (patterns B–E). The figure is derived from the data and classification scheme of Bessen and co-workers [29,30]
and is copied with permission from [31,32].
doi: 10.1371/journal.pone.0078719.g001
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deleted in-frame, was constructed as follows. The region of
mrp upstream of the A-repeats and the region of mrp
immediately downstream of the A-repeats were amplified by
PCR, sequentially inserted and ligated in-frame into the
pTrcHis vector, then expressed and purified as above.
Enzyme-linked immunoassays for binding of IgG and
fibrinogen to M type 4 S. pyogenes and its mutants
The wild type strain SP4 and the indicated mutants were
grown overnight in THY, washed in phosphate buffered saline
(PBS), and adjusted to an OD530 of 0.4 in PBS. Microtiter wells
were coated with 100 µl of the streptococcal suspension for 30
min at 37 °C, then washed and blocked with 1% BSA in PBS.
The wells were then reacted with various concentrations of
peroxidase-labeled, human IgG or biotinylated, human
fibrinogen for 30 min at 37 °C. The wells treated with
peroxidase-labeled, human IgG were then washed and 100 µl
of the substrate tetramethylbenzidine (TMB) was added. For
wells treated with biotinylated fibrinogen, the wells were
incubated with 1 µg/ml of Neutravidin-peroxidase for 30 min at
37°C, then washed and the TMB substrate added. The
absorbance at 650 nm was recorded after color development.
Blanks consisted of wells coated with BSA instead of
streptococci and then treated as described above. Assays were
done in quadruplicate.
Enzyme-linked immunoassays for expression of
surface proteins in SP4 and SP4∆A
The parental strain SP4 and its mutant SP4ΔA were grown
overnight in THY, washed in PBS and used to coat microtiter
wells as described above. The coated wells were reacted for
30 min at 37°C with rabbit anti-sMrp4(3-17) and anti-
sEmm4(1-30) diluted 1:500 in Tris-saline-BSA (0.05 M Tris-
HCl, 0.15 M NaCl, 1 mg/ml bovine serum albumin, pH 7.4)
containing 10% pig serum to block non-immune binding of
immunoglobulins. The wells were then washed and reacted
with a 1:2000 dilution of peroxidase-labeled, goat anti-rabbit
IgG diluted in Tris-saline-BSA. After 30 min at 37°C the wells
were washed, 100 µl of TMB substrate added and the
absorbance at 650 nm was recorded after color development.
Control wells were reacted under the same conditions with
normal rabbit serum to determine the degree of non-specific
binding. Assays were done in quadruplicate.
Assays for effect of animal sera and animal IgG on the
binding of human IgG to Mrp
Microtiter wells were coated with 100 µl of 2.5 µg/ml of
rMrp(1-328) in sodium bicarbonate (pH 9.5) for 1 hour at 37°C.
The wells were washed and blocked with 1% BSA in PBS.
Afterwards, 100 µl of 1 µg/ml of peroxidase-conjugated human
IgG in a 10% solution of the indicated animal serum or in
various concentrations of animal IgG diluted in Tris-saline-BSA
were added to the appropriate wells. The positive control
consisted of 1 µg/ml of peroxidase-conjugate human IgG in
Tris-saline-BSA. Wells coated with BSA and treated as above
served as negative controls. The wells were incubated at 37°C
for 30 min, washed with Tris-saline, and 100 µl of the TMB
substrate added. The absorbance at 650 nm was recorded
after color development. Percent inhibition was calculated
using the formula: % inhibition = [1- (A650 of animal serum (or
animal IgG)/A650 of positive control)] x 100. Assays were done
in quadruplicate.
Competitive binding assays for effect of IgG
subclasses, F(ab’)2 and Fc regions of IgG on binding of
IgG to Mrp
Microtiter wells were coated with 2.5 µg/ml of rMrp(1-328)
and then blocked with 1 mg/ml BSA in PBS. A 100 µl aliquot of
a solution of 1 µg/ml peroxidase-conjugated human IgG and
various concentrations of human IgG subclasses 1-4 or the
F(ab’)2 or the Fc fragment of human IgG in Tris-saline-BSA +
0.05% Tween-20 was added to the wells and incubated at
37°C for 30 min. The wells were then washed, TMB substrate
added and the absorbance at 650 nm recorded after color
development. Negative controls consisted of wells coated with
BSA and treated as described above. Positive controls
consisted of Mrp-coated wells treated with 1 µg/ml peroxidase-
conjugated human IgG in Tris-saline-BSA + 0.05% Tween-20.
Percentage of inhibition was calculated using the formula: %
inhibition = [1- (A650 of binding of IgG in solutions containing the
F(ab’)2 (or Fc, or IgG1-4)/A650 of positive control)] x 100. Assays
were done in triplicate.
Enzyme-linked immunoassays to map the IgG-binding
domain of Mrp
To map the IgG-binding domains of Mrp4, microtiter wells
were coated with 10 µg/ml of the indicated recombinant
peptides of Mrp for 30 min at 37 °C and then blocked with 1%
BSA in PBS for 30 min at 37 °C. Various concentrations of
peroxidase-labeled human IgG in Tris-saline-BSA were then
added to the wells and incubated for 30 min at 37 °C. After
washing, the TMB substrate was added, and the absorbance at
650 nm was recorded after color development. Negative
controls consisted of wells coated with BSA and treated as
described above. Control assays using antiserum against the
polyhistidine tag indicated that all of the histidine-tagged
recombinant proteins of Mrp coated the microtiter wells to a
similar degree. Assays were done in triplicate.
Competitive binding assays comparing a single A-
repeat to multiple A-repeats of Mrp as inhibitors of
binding of human IgG to Mrp
Microtiter wells were coated with rMrp(1-328), blocked with
BSA, and then reacted with peroxidase-labeled, human IgG in
various concentrations of rMrp(150-185) (a single A-repeat) or
rMrp(150-255) (three A-repeats) for 30 min at 37°C. The wells
were then washed, the TMB substrate added and the
absorbance at 650 nm recorded after color development.
Assays were done in triplicate.
Streptococcal growth in human blood
For growth assays in human blood, SP4 and its mutant
SP4ΔA, were grown at 37°C in Todd-Hewitt broth
supplemented with 1% yeast extract (THY) to an OD530 of 0.08
and diluted 1:10,000 in THY. A 50 µl aliquot of this dilution was
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added to tubes containing 450 µl of heparinized, human blood.
The mixtures were rotated for 3 hours at 37 °C and the number
of CFU were determined by plating dilutions on blood agar
plates. The experiments were designed to provide an inoculum
in the range of 100 to 300 CFU and the number of CFU in the
inoculum was determined by plating on blood agar. The blood
of donors was screened to ensure that their blood did not
contain antibodies that could opsonize S. pyogenes and alter
their growth in blood.
Ethics statement
All blood donors signed a written informed consent and the
study and the consent form were approved by the Institutional
Review Board of the University of Tennessee Health Science
Center.
Results
Role of Mrp in binding IgG on the streptococcal surface
To evaluate the role of Mrp in the binding of IgG by S.
pyogenes, the binding of human IgG to the parental, wild type
strain SP4 was compared to that of the Mrp-negative mutant
MP4 and various other mutants of SP4 defective in expressing
other, major proteins on the surface of S. pyogenes. The wild
type strain SP4 bound human IgG in a dose-related fashion
(Figure 2). Inactivation of Mrp reduced IgG binding by ~70%,
whereas inactivation of Emm, Enn, Sof, or Sfbx had only minor
effects on binding. That inactivation of Mrp did not completely
reduce IgG binding was not surprising as other streptococcal
surface components such as Emm also bind IgG [7]. However,
these findings clearly indicate that Mrp is the major IgG-binding
protein on SP4.
Figure 2.  Mrp is the major IgG-binding protein in M type 4 S. pyogenes.  Microtiter wells were coated with SP4, the wild type
strain of M type 4 S. pyogenes, and the indicated mutants of SP4. The wells were then reacted with various concentrations of
peroxidase-conjugated, human IgG. After addition of substrate the binding was determined by measuring the absorbance at 650
nm. BSA served as a negative control. Experiments were done in quadruplicate and the mean ± standard deviation is shown.
doi: 10.1371/journal.pone.0078719.g002
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Selective binding of human IgG by Mrp
To determine if Mrp4 selectively binds to human IgG, IgA, or
IgM, microtiter wells were coated with rMrp and reacted with
peroxidase-labeled human IgG, IgA, or IgM. Mrp4 strongly
bound to human IgG but not to human IgM, or IgA (Figure 3A).
These findings are consistent with those of others who also
found that Mrp selectively bound to human IgG [7,16,18,21].
To examine the potential for host specificity in binding,
various animal sera were tested for their ability to block the
binding of human IgG to Mrp (Figure 3B). Human, pig and
monkey sera were the best inhibitors of binding. Horse, rabbit
and donkey sera partially inhibited binding. Goose, guinea pig,
rat, chicken, cow, mouse and goat sera had little to no effect on
binding of human IgG to Mrp.
It is possible that animal sera may contain other components
that could bind to Mrp and sterically hinder interactions with
IgG. Therefore, various concentrations of purified IgG from
different animals were also tested for their ability to block the
binding of human IgG to Mrp (Figure 4). The results essentially
reflected those obtained with animal sera. For a better
comparison of binding, the concentration required for 50%
inhibition was calculated for each purified IgG (Table 1).
Human IgG was the most effective inhibitor requiring 6 µg/ml to
achieve 50% inhibition followed by pig (20 µg/ml), horse (29
µg/ml) rabbit (40 µg/ml) and monkey IgG (50 µg/ml). Thus,
human IgG was > 3-fold better inhibitor than pig IgG, the one
closest to human IgG in blocking binding. Mouse, rat, goat,
sheep, cow, guinea pig, donkey and chicken IgG were
ineffective inhibitors.
Most immunoglobulin-binding proteins of bacteria bind
immunoglobulins via the Fc domain. Mrp is no exception. The
Fc domain of human IgG blocked the binding of human IgG to
rMrp(1-328), whereas the F(ab’)2 fragment of human IgG had
little effect on binding (Figure 5). These findings agree with
those of Heath et al. [16] who found that Mrp from an M type 76
strain of S. pyogenes bound human IgG via its Fc domain.
To further examine the binding of Mrp to human IgG, each of
the subclasses was tested for its ability to competitively inhibit
the binding of peroxidase-labeled human IgG to Mrp (Figure 6).
The concentration required to inhibit 50% binding of
peroxidase-labeled IgG was 1.2 µg/ml for IgG1, 15 µg/ml for
IgG2, 30 µg/m for IgG3, and 7.4 µg/ml for IgG4. The finding that
IgG3 was the least effective inhibitor was not unexpected
because of previous reports that it bound poorly or not at all to
Mrp [7,12,22].
Mapping of the IgG-binding domain of Mrp
To localize the IgG-binding domain of Mrp, various
recombinant peptides of Mrp were constructed, purified and
tested for binding IgG and fibrinogen by ELISA. A summary of
the results is shown in Figure 7 (top panel). As expected, full-
length rMrp(1-328) bound both human IgG and human
fibrinogen. Both rMrp(150-185), which contains a single A-
repeat, and rMrp(150-255) which contains three A-repeats,
bound IgG but did not bind fibrinogen. Both rMrp(150-185) and
Figure 3.  Binding of immunoglobulins to Mrp and inhibition of binding by animal sera.  A. Binding of peroxidase-labeled
human IgG, human IgM or human IgA to microtiter wells coated with rMrp. B. Inhibition of binding of peroxidase-labeled human IgG
to rMrp by a 10% solution of serum from the indicated animals. Experiments were done in triplicate and the mean ± standard
deviation is shown.
doi: 10.1371/journal.pone.0078719.g003
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rMrp(150-255) blocked the binding of human IgG to Mrp, but
rMrp(150-255) was ~40-fold more effective inhibitor than
rMrp(150-185) (Figure 8).
The above results indicate that the A-repeat region of Mrp4
contains the IgG-binding domain and is consistent with the
results of Heath et al. [16] who found that human IgG binds to
the A-repeats of Mrp from an M type 76 strain of S. pyogenes.
To confirm that the A-repeats are the only IgG-binding domain
within Mrp, a recombinant protein was constructed in which the
DNA encoding the A-repeat region was deleted in-frame and
tested for binding human IgG. This construct failed to bind
human IgG but it still retained the ability to bind fibrinogen
(Figure 7, top panel). Previous work [11] indicated that there
are two fibrinogen-binding domains in the N-terminus of Mrp4
as illustrated in the middle panel of Figure 7. Our data indicate
that the binding domains for IgG and fibrinogen are separate
and distinct. Supporting this concept is the finding that purified,
human fibrinogen did not block the binding of IgG to Mrp (data
not shown).
Role of the A-repeats of Mrp in the growth of S.
pyogenes in human blood
The finding that inactivation of Mrp dramatically reduced IgG
binding provided clear evidence that Mrp is a major IgG-binding
protein in S. pyogenes that express Mrp. However, inactivation
of Mrp not only reduces IgG binding by S. pyogenes, but it also
reduces the binding of fibrinogen to S. pyogenes, which is
involved in resistance to phagocytosis [5]. Therefore,
evaluation of the role of IgG binding to Mrp in the growth of S.
pyogenes in human blood must be done without altering the
binding of fibrinogen to Mrp on the surface of the streptococci.
To accomplish this a mutant, SP4ΔA, was engineered that
expresses Mrp with an in-frame deletion of the DNA encoding
the A-repeats of Mrp. We compared the levels of expression of
Emm4 and Mrp4 of this mutant to that of wild type to ensure
that the expression of these key proteins was not decreased by
the introduction of this mutation. The expression of Mrp in
SP4ΔA was virtually identical to that of its wild type parent, SP4
(Figure 9). There was a slight increase in reactivity of anti-
Figure 4.  Inhibition of the binding of human IgG to Mrp by IgG from various animals.  Microtiter wells were coated with rMrp
and the binding of peroxidase-labeled human IgG was determined in the presence of the indicated concentrations of purified IgG
from animals. Experiments were done in quadruplicate and the mean is shown.
doi: 10.1371/journal.pone.0078719.g004
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sEmm4(1-30) serum with SP4ΔA as compared to that of SP4.
The reason for this slight increase is not clear but it has been
suggested that alterations of one surface protein may provide
enhanced access of antibodies to another surface protein [5].
However, it is clear that there was no significant reduction in
the expression of Mrp4 or Emm4 on the surface of the
streptococci due to this mutation.
Next, it was critical to determine if mutant SP4ΔA that did not
bind IgG would still bind fibrinogen. The binding of fibrinogen
by SP4 and SP4ΔA was virtually identical, but there was a
dramatic reduction in the binding of human IgG by SP4ΔA
when compared to SP4 (Figure 10). These data clearly indicate
that the A-repeat region of Mrp is the major IgG-binding
receptor on the surface of SP4. Furthermore, the finding that
fibrinogen binding of SP4ΔA was similar to that of SP4
provided additional evidence that the expression levels of Mrp
was not altered by the in-frame deletion of the A-repeats,
because Mrp is the major fibrinogen-binding protein in SP4 [5].
To evaluate the effect of this mutation on resistance to
phagocytosis, the growth of SP4 and SP4ΔA in human blood
was compared (Table 2). The multiplication factor of SP4 was
133.7 ± 16, whereas the multiplication factor of SP4ΔA was
27.1 ± -.7. This indicates that the loss of the A-repeats within
Mrp reduced growth of S. pyogenes in human blood by ~80%.
Discussion
Resistance to phagocytosis is a key mechanism contributing
to the virulence of S. pyogenes. Previous work indicated that
Mrp contributes to this resistance by binding fibrinogen and
preventing complement deposition [5]. Purified Mrp has also
been shown to bind human IgG, but it was not known if Mrp is
the major surface protein that binds IgG or if this binding has
any role in resistance to phagocytosis in human blood. In this
report, we present our findings indicating that the Fc-mediated
binding of human IgG to the A-repeats of Mrp does confer
Table 1. The concentration of various animal IgG required
to achieve fifty percent inhibition of the binding of human
IgG to Mrp4.














*. the 50% concentration was determined from data in Figure 4.
doi: 10.1371/journal.pone.0078719.t001
resistance to phagocytosis and enhances growth of S.
pyogenes in human blood. These findings include: (i)
inactivation of Mrp resulted in a dramatic decrease in the
binding of human IgG by S. pyogenes; (ii) purified, recombinant
peptides expressing the A-repeats of Mrp bound human IgG
whereas other recombinant peptides of Mrp did not; (iii) Mrp
bound to the Fc domain of human IgG; (iv) SP4ΔA, a mutant
expressing Mrp with an in-frame deletion of A-repeats,
exhibited reduced binding of human IgG but still bound
fibrinogen equal to SP4; (v) growth of SP4ΔA in human blood
was reduced by 80% compared to its wild type parent.
These results indicate that Mrp is a key virulence factor that
contributes to resistance to phagocytosis not only by binding
fibrinogen, but also by binding human IgG. The clinical
relevance of this finding is that Mrp is widely expressed by
strains of S. pyogenes causing infections: ~75% of serotypes
found during a surveillance by the Center for Disease Control
during 1995-2001 contain the gene for Mrp.
Unlike M proteins that exhibit high variability within their N-
termini, Mrp’s are only semi-variable in their N-termini. Analysis
of Mrp sequences indicated that there are three major groups
of Mrp based on variability within their N-termini and within
each major group the N-termini are highly conserved [11]. In
addition, the C-terminal regions of Mrp are highly conserved.
Thus, the overall similarity among Mrp from different serotypes
is quite high and ranges from 80 to 98% [11]. Therefore,
functions that are associated with domains within the
conserved region of one Mrp are likely to be found in all Mrp’s.
Supporting this notion is the finding that all mrp sequenced to
date contain the A-repeat region, indicating that the ability to
bind IgG is likely to be a common trait among strains
expressing Mrp [11]. Further support for this concept is the
finding that human IgG binds to Mrp’s representing all three
groups of Mrp [7,16,17].
The A-repeats of Mrp appear to contain unique sequences
that bind IgG. The IgG-binding domain of Mrp does not have
any significant degree of similarity to the IgG-binding domains
of M proteins and protein H, as described by Pack et al. [23] or
to the IgA-binding domains of M proteins and M-like proteins
described by others [9,13,24].
Our competitive inhibition data suggest that the A-repeats of
Mrp preferentially bind IgG subclasses in the order of
IgG1>IgG4>IgG2>IgG3. Mrp bound IgG1 6-fold better than IgG4,
12-fold better than IgG2 and 25-fold better than IgG3. Previous
investigations using western blot analyses suggested that Mrp
binds human IgG1, IgG2, and IgG4 but not IgG3 [7,12], whereas
another investigation using Ouchterlony immunodiffusion
analysis indicated that Mrp bound all of the subclasses, but
bound IgG3 weakest [22]. In prior analyses, where the binding
of IgG3 was not detected, only one concentration was used in
western blots, whereas we used a competitive inhibition assay
with low to high concentrations of IgG, which may detect
weaker binding.
The preferential binding of human IgG to Mrp may have a
role in host specificity. GAS infections are almost entirely
restricted to the human host and the findings that Mrp
selectively binds human IgG and that this binding enables the
GAS to resist phagocytosis in human blood, suggest that this
Binding of IgG by Mrp Enhances Growth in Blood
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binding may be a factor contributing to this host restriction. In
this regard, it is interesting to note that the mouse model is
widely used for testing the virulence of GAS, yet mouse IgG
does not bind to Mrp. Future work should examine whether a
transgenic mouse expressing human IgG would be more
susceptible to GAS infections.
The molecular mechanism(s) whereby IgG-Mrp interactions
contribute to resistance to phagocytosis is not entirely clear.
One mechanism may be that the acquisition of IgG on the
surface of the streptococci makes the surface of the bacteria
appear more like the host and thereby, reduces the ability of
the host to detect the bacteria. It is not suggested that IgG
Figure 5.  Mrp binds to the Fc region of human IgG.  Various concentrations of the Fc or the F(ab’)2 fragment of human IgG were
mixed with peroxidase-labeled human IgG and added to microtiter wells coated with Mrp and the percentage of inhibition of the
binding of IgG was determined as described in Materials and Methods. Experiments were done in triplicate and the mean ± SD is
shown.
doi: 10.1371/journal.pone.0078719.g005
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binding alone may accomplish this as GAS bind a large
number of blood proteins and become coated with these host
proteins. However, the binding of IgG to Mrp may contribute to
this process. One possible consequence of this coating is the
diminished deposition of complement onto the streptococcal
surface. It remains to be determined if Mrp-IgG interactions
have any effect on complement deposition.
There are other potential mechanisms that may come into
play in the presence of antibodies directed against surface
antigens of S. pyogenes. The binding of IgG via its Fc may
prevent antibodies from binding via its antigen specific Fab
domains and thereby reduce opsonization. IgG bound via its Fc
domain to Mrp would not be able to bind to Fc receptors on
phagocytic cells. In this regard, the streptococcal, IgG-cleaving
enzyme, IdeS, was found to preferentially degrade IgG bound
to streptococcal proteins via Fab interactions compared to IgG
bound via Fc interactions [25]. Thus, Mrp could act in concert
with IdeS to prevent phagocytosis. IdeS would degrade IgG
bound to surface antigens via its Fab while IgG bound to Mrp
by the Fc regions would not be degraded by IdeS, but would
prevent interactions with Fc receptors on phagocytic cells.
Figure 6.  Selective binding of Mrp to subclasses of IgG.  Various concentrations of IgG1, IgG2, IgG3 and IgG4 were tested for
their ability to inhibit the binding of human IgG to Mrp as described in Materials and Methods. Assays were done in triplicate and the
average is shown.
doi: 10.1371/journal.pone.0078719.g006
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A similar mechanism for the IgA-binding proteins Emm22
(also termed Sir22) and Emm4 (also termed Arp4) has been
proposed by Woof [26], where these IgA-binding proteins were
found to inhibit the binding of IgA to FcαR. Emm4 was also
found to inhibit FcαR triggering of the respiratory burst in
neutrophils [13]. It was suggested that when IgA binds to
specific antigens on the surface of S. pyogenes, the Fc domain
of the bound IgA molecules then interacts with these Emm
proteins and thereby, interferes with binding to their Fc
receptors on phagocytes. That IgA binding to Emm22 is
involved in resistance to phagocytosis was shown by Carlsson
et al. [6] who found that an in-frame deletion of the IgA-binding
domain in Emm22 reduced growth of S. pyogenes in human
blood. While the Mrp-binding domain has been determined to
be in the Fc domain of IgG, it is not known if this binding site
overlaps with that for Fcγreceptors on IgG. Thus, it is not
Figure 7.  Mapping of the IgG-binding domain of Mrp.  Top panel. Recombinant proteins spanning the indicated amino acid
residues of Mrp were tested for binding human IgG or human fibrinogen by ELISA and the results are summarized here. Also tested
was rMrpΔA, in which the DNA encoding the A-repeats were deleted in-frame as indicated by the triangle. Middle panel. The
predicted sequence of the mature form of Mrp4 (leader sequence removed) is shown and the underlined sequences indicate the
location of the two fibrinogen-binding domains (FBD1 and FBD2). Arrows indicate the beginning of each of the A-repeats. Bottom
panel. A comparison of the sequences of the A-repeats. White letters on black background indicate amino acids that are conserved
in the repeats.
doi: 10.1371/journal.pone.0078719.g007
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known if Mrp will compete with Fcγreceptors for binding the Fc
regions of IgG. Further work is needed to determine the
molecular mechanism(s) whereby Mrp confers resistance to
phagocytosis in human blood.
It was recently suggested by Nordenfelt et al. [27] that the
Fc-mediated binding of IgG by S. pyogenes does not provide
protection against phagocytosis in blood. This was based, in
part, on the finding that expression of protein H in an M1 strain
of S. pyogenes failed to protect against phagocytosis when the
streptococci were coated with antibodies that bound via
antigen-specific Fab domain of IgG. However, it is well known
that opsonic antibodies specific for certain streptococcal
surface antigens can promote phagocytosis and killing of GAS,
thereby overcoming the ability of GAS to resist phagocytosis
Figure 8.  Peptide with multiple A-repeats is a better inhibitor of IgG binding to Mrp.  The indicated concentrations of
rMrp(150-185) (A1, a single A-repeat) or rMrp(150-255) (A3, three A repeats) were mixed with peroxidase-labeled, human IgG and
the binding to microtiter wells coated with rMrp was determined as described in Materials and Methods. Assays were done in
triplicate and the average is shown.
doi: 10.1371/journal.pone.0078719.g008
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and multiply in human blood [28]. One of the major differences
between our experiments and those of Nordenfelt et al. is that
we utilized whole blood from donors who had been screened
for the absence of opsonic antibodies, whereas in their study
the IgG preparations used in phagocytosis assays appeared to
contain opsonizing antibodies, because their IgG preparations
promoted phagocytosis of GAS and by definition IgG that
promotes phagocytosis is considered opsonic. Another,
important difference between these two studies is that the M1
strain used by Nordenfelt et al. does not contain the gene for
mrp, whereas Mrp is clearly expressed in the M type 4 strain
used in our study. Although the Emm1 strain does bind IgG,
this binding is mediated by protein H and Emm1 and it may be
that this binding will not have the same impact on GAS growth
in blood as that found for IgG binding to Mrp.
In summary, the A-repeats of Mrp contribute to virulence of
group A streptococci by binding IgG and enhancing resistance
to phagocytosis in human blood. Its preferential binding of
Figure 9.  Expression of Emm and Mrp in SP4 and SP4ΔA.  Microtiter wells were coated with the wild type strain SP4 and its
mutant SP4ΔA and reacted with antisera against a synthetic peptide of Emm4 or Mrp4 as described in Materials and Methods.
Assays were done in triplicate and the mean ± SD is shown.
doi: 10.1371/journal.pone.0078719.g009
Figure 10.  Role of the A-repeats of Mrp in the binding of human IgG and fibrinogen by S. pyogenes.  Microtiter wells were
coated with wild type M4 S. pyogenes (SP4) and its mutant SP4ΔA. The wells were then incubated with indicated concentrations of
human fibrinogen (left panel) or human IgG (right panel). The amount bound was determined as described in Materials and
Methods. Assays were done in triplicate and the mean ± SD is shown.
doi: 10.1371/journal.pone.0078719.g010
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human IgG may contribute to the host specificity of this
organism. Because Mrp is a virulence factor, its potential as a
Table 2. Effect of deletion of A repeats of Mrp on growth of
S. pyogenes in human blood.
 Strain Inoculum Total CFU MFa
Exp 1 SP4 138 17,300 125.3
 SP4∆A 254 6,750 26.5
Exp 2 SP4 178 22,100 124.2
 SP4∆A 258 7,200 27.9
Exp 3 Sp4 182 27,600 151.6
 SP4∆A 284 7,650 26.9
Mean MF ± sdb SP4 SP4∆A   133.7 ± 16 27.1 ± 0.7
The indicated inoculum of wild type S. pyogenes (SP4) and its mutant SP4∆A was
added to human blood, rotated for 3 hours at 37°C and the total number of CFU
determined.
a. MF = multiplication factor, calculated by dividing the total CFU by the inoculum.
b. Means are significantly different, p = 0.0003.
doi: 10.1371/journal.pone.0078719.t002
vaccine candidate should be investigated to determine if
antibodies directed against the A-repeats are opsonic. Such
antibodies might be effective not only by directly opsonizing the
bacteria but also by blocking interactions between the A-
repeats of Mrp and the Fc domain of IgG.
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